(5-Isopropylpyrimidin-2-YL)methanamine | 944898-44-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (5-Isopropylpyrimidin-2-YL)methanamine
• 英文别名: (5-propan-2-ylpyrimidin-2-yl)methanamine
• CAS: 944898-44-6
• 化学式: C₈H₁₃N₃
• mdl: MFCD10697248
• 分子量: 151.21
• InChiKey: YLKFSDBNPARCCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• FACTOR IXA INHIBITORS
  申请人：Boyle Craig

  公开号：US20140219989A1

  公开（公告）日：2014-08-07

  The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了公式（I）所述的化合物或其药学上可接受的盐。本发明还提供包含一种或多种所述化合物的制药组合物，以及使用所述化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。
• [EN] HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS<br/>[FR] COMPOSÉS HÉTÉROARYLE POUVANT ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES COGNITIFS
  申请人：UNIV COLLEGE CARDIFF CONSULTANTS LTD

  公开号：WO2022234271A1

  公开（公告）日：2022-11-10

  The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3, Ring A and Ring B are as described herein. The compounds have affinity for α5-subunit-containing GABAAreceptors. The invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with α5-GABAAreceptors, including depression and cognitive impairment, for example, congintive impairment associated with a psychotic disorder such as schizophrenia.

  本发明提供了式（I）的化合物，以及其药学上可接受的盐：其中X1，X2，X3，R3，环A和环B如本文所述。该化合物具有与α5亚单位含量的GABAA受体的亲和力。本发明进一步提供了制备式（I）化合物的方法，包括含有该化合物的药物组合物以及将其用作治疗与α5-GABAA受体相关的疾病和障碍的药物，包括抑郁症和认知障碍，例如与精神疾患如精神分裂症相关的认知障碍。
• Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170066783A1

  公开（公告）日：2017-03-09

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an aryl, heteroaryl or heterocycle (R 32 ) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
• TRICYCLIC GYRASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170369498A1

  公开（公告）日：2017-12-28

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
• US9161924B2
  申请人：——

  公开号：US9161924B2

  公开（公告）日：2015-10-20